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http://dx.doi.org/10.1016/j.pedneo.2Background: Bronchopulmonary dysplasia (BPD) is a chronic lung disease that causes significant
morbidity and mortality in premature infants. Inflammation and oxidative injury play an impor-
tant role in the pathogenesis of BPD. Resveratrol is an antioxidant and anti-inflammatory
agent. In this study, the histopathological and biochemical effects of resveratrol on a
hyperoxia-induced lung injury model in newborn rats were investigated.
Methods: The experiment was performed on newborn rat pups from the 3rd to 13th postnatal
day and they were randomly divided into four groups: Group 1 (air-exposed þ saline,
n Z 10), Group 2 (air-exposed þ resveratrol, n Z 11), Group 3 (hyperoxia-exposed þ saline,
n Z 6) and Group 4 (hyperoxia-exposed þ resveratrol, n Z 7). Resveratrol was administered
(30 mg/kg/day) intraperitoneally. The histopathological effects of resveratrol on lung tissue
were assessed by alveolar surface area, fibrosis, and smooth muscle actin (SMA) score, and
the biochemical effects on lung tissue were assessed by glutathione (GSH), superoxide dismut-
ase (SOD), nitric oxide (NO), tumor necrosis factor-a (TNF-a), and nuclear factor kappa B
(NF-kB) levels.
Results: The alveolar surface area, fibrosis, SMA score, and NO levels were found to be signif-
icantly higher in Group 3 compared with Group 1 (p < 0.05). In addition, it was found that re-
sveratrol treatment significantly reduced the SMA score and the NO and TNF-a levels, and
increased the GSH and SOD levels in the hyperoxia group (p < 0.05).
Conclusion: This experimental study showed that oxidative stress and NO contributed to the
pathogenesis of hyperoxia-induced lung injury, and that resveratrol had a preventive effect
on hyperoxic lung injury through its anti-inflammatory and antioxidant properties.
Copyright ª 2014, Taiwan Pediatric Association. Published by Elsevier Taiwan LLC. All rights
reserved.of Pediatrics, School of Medicine, Pamukkale University, C¸ocuk Poliklinik Binası, Kat 2, Kınıklı 20070,
mail.com (E. Go¨zkeser).
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chronic lung disease of prematurity, is a major cause of
long-term morbidity and mortality in premature infants.
Despite advances in neonatal critical care including ante-
natal steroids, surfactant replacement therapy, gentle
ventilation/nasal continuous positive airway pressure, and
reduced oxygen concentration, the number of infants with
BPD has increased as the survival time of very small pre-
mature infants has increased.1 Various factors contribute to
the pathogenesis of this disease, including a susceptible
host with immature lung structure, and the developmental
deficiencies of factors crucial to lung development and
function, such as surfactant, nitric oxide (NO), innate im-
mune defense, and antioxidant capability.1 Oxidant injury
and inflammation are thought to be dominant mechanisms
in the pathogenesis of BPD.2 Although there are no safe and
effective preventive therapies, new treatment strategies
remain promising for the prevention of BPD.1
Resveratrol (3,5,40-trans-trihydroxystilbene) is a natural
phytoalexin present in grapes, peanuts, mulberries, and red
wine. The anti-inflammatory and antioxidant activities of
resveratrol have been well documented in many different
studies.3e5 Its anti-inflammatory effect is related to inhib-
iting oxidation, leukocyte priming, and expression of in-
flammatory mediators. It has been also reported in
experimental studies that resveratrol reduced lung injury,
such as sepsis or bleomycin-induced lung injury.4,5
However, no report exists related to its activity on an
experimental model of BPD in rats; therefore, we investi-
gated the histopathological and biochemical effects of
resveratrol on hyperoxia-induced lung injury in neonatal
rats.
2. Materials and methods
2.1. Animals
This study was approved by the Pamukkale University Ani-
mal Research Committee and was performed on newborn
(3e13 days old) Wistar albino rat pups whose mothers had
been kept under standard conditions.
3. Experimental design
Wistar albino rat pups were delivered spontaneously and
reared with their dams (n Z 4) until the time of the
experimentation. Afterward, the rat pups were randomly
divided into four groups: air-exposed þ saline group (Group
1, n Z 10), air-exposed þ resveratrol group (Group 2,
n Z 11), hyperoxia-exposed þ saline group (Group 3,
n Z 10), and hyperoxia-exposed þ resveratrol treated
(Group 4, nZ 11). The experiment began on postnatal day
3 and continued until postnatal day 13 (day of birth Z day
0). A hyperoxia-induced lung injury rat model of BPD
was used.6 Groups 3 and 4 (hyperoxia-exposed groups)
were placed in an oxygen chamber (Plexiglas
chamber), into which oxygen was continuously delivered
(FiO2 Z 0.90  0.02) using a flow of 2 L/minute, and thegroups were monitored twice daily (Anesthetic Gas Monitor,
Drager 1996). The rat pups in Groups 2 and 4 received
resveratrol (Sigma-Aldrich Chemical Co., St. Louis, MO,
USA) intraperitoneally at a dose of 30 mg/kg beginning on
postnatal Day 3 and daily through to postnatal Day 13.4 The
other rat pups in Groups 1 and 3 received only saline (0.9%)
intraperitoneally at the same dose and time. All animals
were returned to their mothers, kept in a normothermic
environment and humidity (at 22e25C and 60e70% hu-
midity), and breast-fed. CO2 was removed by soda lime
absorption.7 Nursing mothers were not treated but were
rotated between room air and hyperoxia every 24 hours. All
animals were raised in the same room and all other condi-
tions were the same. On postnatal Day 14, all animals were
killed by intraperitoneal injection of pentobarbital sodium
(200 mg/kg). Alveolar surface area (ASA) score, lung fibrosis
score, smooth muscle actin (SMA) score, glutathione (GSH),
superoxide dismutase (SOD), and NO activities, tumor ne-
crosis factor-a (TNF-a) and nuclear factor kappa B (NF-kB)
were measured on the lung tissue samples. The weight of
the rats was also evaluated throughout the experiment.3.1. Preparation of specimens
The lungs of the rats were removed by thoracotomy and the
right lungs were inflation-fixed via a tracheal cannula using
10% neutral formaldehyde solution for histological evalua-
tion. Each lobe of fixed lung tissue was separated, placed in
cassettes, and embedded in paraffin after tissue process-
ing. The tissues were paraffin sectioned (5 mm) and later
stained with hematoxylin and eosin (H&E), and Masson tri-
chrome stain after deparaffinization. These stained lung
tissue samples were evaluated for histopathological
changes by a pathologist in a blind fashion. The left lungs
were gently perfused with 10 mL of 0.9% saline to remove
blood, and then placed in Eppendorf tubes and stored in a
freezer at 80C for biochemical analyses.74. Histological assessment of lung fibrosis and
ASA
The tissue sections of the right middle and lower lung lobes
were stained with H&E and Masson trichrome stain for the
evaluation of alveolar fibrosis. Fields in which large vessels
and airways were present were not included. The images
from the nonoverlapping peripheral zone of the samples, a
minimum of 10 lung fields, were examined at 10 magni-
fication. Each lung section was evaluated histologically and
scored as follows: 0: absence of alveolar fibrosis; 1: mild
fibrosis; 2: moderate fibrosis; and 3: marked fibrosis.8
The tissue sections of the right middle lobe were stained
with H&E for the evaluation of ASA. ASA was measured by a
pathologist using a computer-assisted image analyzer sys-
tem consisting of a microscope. The images from the pe-
ripheral zone of the samples were examined at 4
magnification and 10 nonoverlapping fields were measured
semiquantitatively.6 The decrease in ASA was evaluated
histologically and scored as follows: 0: no decrease; 1: mild
decrease; 2: moderate decrease; and 3: marked decrease
in ASA.9
354 O¨.M.A. O¨zdemir et al5. Immunohistochemical assessment of lung
SMA expression
The lung SMA expression was visualized using the avi-
dinebiotineperoxidase method. Embedded lung tissues
from the right lobes were sectioned on poly-L-lysin-coated
slides. The tissue sections were deparaffinized in xylene,
and rehydrated and immersed in distilled water. Endoge-
nous peroxidase activity was blocked using a 0.3% solution
of hydrogen peroxidase in phosphate-buffered saline (PBS).
The primary antibody against SMA (prediluted, Ventana
Medical Systems Inc, Tucson, AZ, USA) was applied for 30
minutes at room temperature and washed in PBS. The
peroxidase activity was visualized with 0.03% 3,30-
diaminobenzidine tetrahydrochloride (Sigma Chemical
Co.) applied for 5 min. After rinsing in deionized water and
counterstaining with hematoxylin, the slides were dehy-
drated and mounted. Appropriate tissue sections were also
labeled as positive and negative controls for the primary
antibody. Ten nonoverlapping microscopic fields were
selected at 10 magnification in a random manner for
immunohistochemical scoring. The degree of positive
staining was evaluated by semiquantitative scoring on a
scale of 1 to 4 for intensity and for distribution.10
5.1. Biochemical analyses
Lung tissues were homogenized at 4C in 50 mM phosphate
buffer solution (pH: 7.4, 1/10 g/mL) containing 0.2 mM
phenylmethanesulfonyl fluoride, 1 mM EDTA, and 1 mM
leupeptin. Homogenates were centrifuged at 10,000 g for 5
minutes. Clear upper supernatant fluid was obtained and
assayed for biochemical analyses including GSH, SOD, NO,
TNF-a, and NFkB. Lung tissue SOD activity was measured by
the method described by Sun et al,11 and NO levels were
measured using a modified version of the Griess reaction, a
method by Navarro-Gonzalves et al.12 The tissue levels of
GSH, TNF-a, and NFkB were measured by commercial
enzyme-linked immunosorbent assay kits (Bender Medsys-
tems GmbH, Campus Vienna Biocenter, Vienna, Austria).
The results of GSH, SOD, NO, TNF-a and NFkB were
expressed as micrograms, nanograms, micromoles, and pi-
cograms per gram of wet tissue, respectively.
5.2. Statistical analysis
For statistical analysis, the results were subjected to
nonparametric tests (Kruskal-Wallis test, Mann-Whitney UTable 1 The histopathologic effects of resveratrol on hyperoxi
Alveolar surface area score
Median (minemax)
Group 1 (n Z 10) 1 (0e1)
Group 2 (n Z 11) 1 (0e1)
Group 3 (n Z 6) 2 (1e3)*
Group 4 (n Z 7) 1 (1e2)y
* Group 3 > Group 1 and Group 2 (p < 0.05).
y Group 4 > Group 1 and Group 2 (p < 0.05).
z Group 3 > Group 1, Group 2 and Group 4 (p < 0.05).test) using the Statistical Package for Social Sciences for
Windows (Version 10.0; SPSS Inc., Chicago, IL, USA), as
appropriate. All values are expressed as median, minimum-
maximum. A p value less than 0.05 was considered
significant.
6. Results
There was no statistically significant difference between
the groups in terms of median weight (10.6 g in Group 1,
11.3 g in Group 2, 10.4 g in Group 3, and 10.2 g in Group 4)
before the experiment (p > 0.05). Eight animals died during
the study, four in Group 3 and four in Group 4. However,
these animals’ lung tissues were not included the study.
Sixty-two percent of neonatal rats exposed to hyperoxia
survived, with most deaths occurring between 7 and 10 days
of life. Prolonged neonatal exposure to hyperoxia adversely
affected growth. At the end of the study, the median
weights of rats in the hyperoxia-exposed groups (12.4 g in
Group 3 and 13.8 g in Group 4) were significantly lower than
those in the air-exposed groups (29.1 g in Group 1 and
25.5 g in Group 2) (p < 0.001). Although the median weight
of rats in Group 4 was higher than that of the rats in Group
3, this result was not statistically significant.
As shown in Table 1, exposure to hyperoxia resulted in a
significant increase in mean ASA and fibrosis when
compared with the air-exposed groups (p < 0.05). In the
hyperoxia-exposed groups, although resveratrol treatment
resulted in lower mean ASA and fibrosis when compared
with saline, these results were not statistically significant
(p Z 0.074).
6.1. SMA immunostaining
The lung SMA scores in the study groups demonstrated a
marked increase in smooth muscle content in the
hyperoxia-exposed animals (p < 0.05, Figure 1). In addi-
tion, the results demonstrated that resveratrol treatment
significantly decreased the SMA scores when compared with
hyperoxia-exposed þ saline animals (p < 0.05). The SMA
scores of the groups are shown in Table 1.
6.2. Biochemical effects of hyperoxia and effects of
resveratrol
In this study, there was no statistically significant differ-
ence for the activities of antioxidant status including SOD
and GSH between the air-exposed and hyperoxia-exposeda-induced lung injury
Fibrosis score
Median (minemax)
SMA score
Median (minemax)
0 (0e1) 1 (1e2)
0 (0e1) 1 (1e2)
2 (1e3)* 9 (4e16)z
1 (1e2)y 4 (2e9)y
Figure 1 Representative light micrographs showing decreased smooth muscle actin (SMA) immunostaining with resveratrol
treatment. (A) Air-exposed þ saline group; (B) hyperoxia-exposed þ saline group (the arrows are pointing to SMA immunostained
areas); (C) hyperoxia-exposed þ resveratol-treated group (SMA immunostain, 10).
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resveratrol treatment significantly increased these antiox-
idant activities when compared with saline (p < 0.05,
Table 2). The lung tissue NO levels were found to be
significantly higher in the hyperoxia-exposed group when
compared with the air-exposed groups The lung tissue NO
levels were found to be significantly higher in the
hyperoxia-exposed þ saline group when compared with the
air-exposed and hyperoxia-exposed þ resveratrol groups
(p < 0.05). In addition, resveratrol treatment significantly
reduced the NO levels (p < 0.05, Table 2). Although it was
found that the hyperoxia-exposed Group 3 had the highest
median NFkB and TNF-a levels, these results were not
statistically significant (p > 0.05). Resveratrol treatment
significantly decreased the levels of TNF-a in the hyperoxia
groups when compared with the hyperoxia-exposed þ sa-
line group (p < 0.05). However, this decreased effect of
resveratrol was not statistically significant for NFkB
(p > 0.05, Table 2).7. Discussion
Despite notable advances in neonatal critical care, BPD
remains a major complication, frequently resulting in
mortality as well as short-term and long-term morbidities.13
It is characterized by an arrest in alveolar and vascular lung
development, inflammation, and abnormal coagulation and
fibrinolysis, resulting in alveolar fibrin deposition and
oxidative stress.14The hallmark features of BPD are a decreased number of
alveoli, increased variability in alveolar size, and intersti-
tial fibrosis.15 There is evidence from animal models that
exposure of the developing lung to high concentrations of
oxygen inhibits alveolus formation and decreases lung sur-
face area.6,7,16 Similar to other animal studies, our study
showed a significant decrease in ASA in rats exposed to
hyperoxia. The histopathological changes in severe airway
injury and alternating sites of overinflation and fibrosis that
used to be seen in older forms of BPD have been replaced
by a milder form that is characterized by alveolar and
capillary hypoplasia and variable interstitial cellularity
and/or fibroproliferation.1,17 In our study, a median alve-
olar fibrosis score was absent in all air-exposed animals.
However, exposure to hyperoxia resulted in moderate
fibrosis in all of the animals, as in previously reported re-
sults.6,7,17 In addition, although we found that resveratrol
treatment in neonatal rats exposed to hyperoxia was
associated with improved ASA and fibrosis compared with
the hyperoxia-exposed þ saline group, these results were
not statistically significant. However, immunostaining for
SMA demonstrated a marked decrease in smooth muscle
content in the hyperoxia-exposed þ resveratrol group. In
contrast, median SMA score was significantly higher in the
hyperoxia-exposed þ saline group than in the other groups.
Therefore, this study showed that resveratrol has a pro-
tective effect on hyperoxia-exposed lung injury in histo-
pathological studies. In many different studies,
investigators have shown that resveratrol has various
pharmacological effects, including anti-inflammatory
properties (such as reducing and regulating the release of
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356 O¨.M.A. O¨zdemir et alinflammatory mediators such as TNF-a, IL-1b, and IL-6),
inhibition neutrophil infiltration, reduction in lung tissue
collagen content, and the improvement of antioxidant de-
fense mechanisms.3e5,18,19 In the current study, we also
found that resveratrol treatment significantly decreased
the lung tissue levels of TNF-a in hyperoxic lung injury.
Pulmonary oxygen toxicity, through the generation of
reactive oxygen species (ROS) and reactive nitrogen species
(RNS) in excess of antioxidant defenses, is likely to play an
essential role in the parenchymal injury of BPD.1,7,20 NO,
either endogenous or exogenous in origin, may function as
either a pro-oxidant or antioxidant. Dawis et al demon-
strated a strong correlation between the products of NO
reactivity and BPD.20 In several studies, it was reported
that a high concentration of NO was produced by inducible
NO synthase (iNOS) in inflammation, and the prevention of
the expression of iNOS might be an important anti-
inflammatory mechanism.20e22 Tsai et al reported that
resveratrol inhibited the induction of iNOS and the activa-
tion of NFkB, and reduced NO generation.21 Thus, the au-
thors concluded that the anti-inflammatory properties of
resveratrol might be mediated by inhibition of iNOS
expression through downregulation of NFkB. We found that
the tissue levels of NFkB in the hyperoxia-exposed þ saline
group were higher than those of other groups, and that
resveratrol treatment reduced NFkB levels; however, these
results were not statistically significant. Recently, Pan and
colleagues also reported that NO-mediated tyrosine nitra-
tion of proteins played an important role in the pathogen-
esis of hyperoxia-induced lung injury and increased nitrite
levels in the damaged lung tissue induced by hyperoxia
exposure in rats.7 In the current study, the NO levels of
hyperoxia-exposed þ saline group rats were significantly
higher than those of the air-exposed groups. Moreover, the
NO levels of the hyperoxia-exposed þ resveratrol group
were significantly lower than those of the hyperoxia-
exposed þ saline group. Thus, we also showed that NO
was a critical mediator of the inflammatory response for
the development of hyperoxia-induced lung injury and that
resveratrol significantly decreased the lung tissue levels of
NO.
The evidence suggests the presence of an oxidant-
antioxidant imbalance in lungs that are at risk of BPD.1
Oxygen may damage the lung cells directly via the gener-
ation of ROS or indirectly via the action of the inflammatory
cells and inflammatory mediators. These responses, in turn,
overwhelm the cellular antioxidant defenses and lead to
the accumulation of toxic levels of ROS.23,24 High concen-
trations of oxygen also increase the formation of other free
radicals, such as NO and peroxynitrite, which harmDNA and
other biomolecules.25 Several studies reported that lung
injury induced by sepsis or bleomycin was coupled with GSH
depletion, and that resveratrol treatment reversed this GSH
depletion.4,5 However, Pan and colleagues reported that
the activities of antioxidant enzymes including SOD, GSH-
peroxidase, and catalase did not change after exposure to
hyperoxia.7 In the current study, the activities of GSH and
SOD, which did not change after exposure to hyperoxia,
were significantly increased by resveratrol treatment.
Previous studies have also shown the antioxidant effects of
resveratrol via elevation of the antioxidant status such as
GSH and SOD.5,26
Effects of resveratrol for rat model of hyperoxia-induced lung injury 357In conclusion, this study showed that NO and oxidative
stress play an important role in the etiopathogenesis of
hyperoxic lung injury, and that resveratrol is effective in
terms of preventing hyperoxic lung injury because of its
anti-inflammatory and antioxidant effects.
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